Peptide Hydrogel Nanoparticle Composite for Localized Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for hydrogel-mediated delivery of nucleic acid-based therapeutics face challenges in achieving clinical viability, particularly in ensuring targeted and controlled release of therapeutic agents to specific tissues, limiting systemic distribution and off-target toxicity.
Innovation Solution
A peptide hydrogel composite is developed, comprising nanoparticles of a nucleic acid molecule complexed with an amphiphilic cationic peptide that is not in a β-hairpin conformation, encapsulated within a fibrillar network of a β-hairpin peptide, allowing for localized delivery and controlled release of the nucleic acid molecules to target tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If nucleic acid molecules are delivered systemically, then therapeutic coverage is improved, but off-target toxicity increases
Solution Approach 1:
The hydrogel composite material provides localized delivery of nucleic acid molecules to specific tissue sites. The material's local presence at the target site allows concentrated therapeutic effect where needed while preventing systemic distribution and associated off-target toxicity. This is achieved through the hydrogel's ability to remain localized at the injection site and release nucleic acids in a controlled manner at the target tissue.
Solution Approach 2:
The hydrogel composite acts as an intermediary carrier that mediates between the nucleic acid therapeutic and the target tissue. This intermediary system enables controlled local release of the therapeutic agent, improving delivery efficiency to the target site while preventing systemic circulation and off-target effects.
2Ease of operation
If hydrogel-mediated delivery is used, then localized delivery is improved, but controlled release capability is insufficient
Solution Approach 1:
The composite material structure nests multiple functional components together: nucleic acid molecules are encapsulated within the hydrogel matrix, which itself is formed from self-assembling peptide nanoparticles. This nested structure enables both localized delivery (through the hydrogel's tissue retention) and controlled release (through the gradual degradation and disassembly of the nested nanoparticle structure).
Solution Approach 2:
The invention uses a composite material system combining hydrogel matrix with embedded peptide nanoparticles. This composite structure provides synergistic functionality: the hydrogel component enables localized delivery and retention at the target site, while the nanoparticle component provides controlled release kinetics through its self-assembled structure that degrades over time.
3Productivity
If peptide complexation is used, then cellular uptake is improved, but nanoparticle stability may be compromised
Solution Approach 1:
The cationic peptides are pre-complexed with the nucleic acid molecules to form stable nanoparticles before hydrogel encapsulation. This preliminary complexation ensures high cellular uptake capability is established before the nanoparticles are embedded in the hydrogel matrix, which then protects them during storage and delivery while maintaining their uptake functionality.
Solution Approach 2:
The composite structure of cationic peptide-nucleic acid nanoparticles provides inherent stability through electrostatic complexation, while the subsequent encapsulation in the hydrogel matrix adds an protective layer that maintains nanoparticle integrity during delivery. The composite system thus achieves both stability and high cellular uptake.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide hydrogel composite enables efficient and localized delivery of nucleic acid molecules, such as miRNA, to target tissues, facilitating cellular uptake and therapeutic effects while minimizing systemic distribution and toxicity, with potential for sustained release and enhanced therapeutic efficacy.
Implementation Method 1
nanoparticles comprising a nucleic acid molecule complexed with an amphiphilic cationic peptide
Implementation Method 2
The peptide hydrogel is formed from a fibrillar network of a second amphiphilic cationic peptide that is in a β-hairpin conformation
Implementation Method 3
The nanoparticle-hydrogel composite displays shear-thin/recovery mechanical properties, which allow the nanoparticle-hydrogel composite and any additional therapeutic dispersed within the hydrogel to be delivered locally to a target location
Implementation Method 4
After delivery, the nanoparticles time-release from the hydrogel matrix to adjacent tissues and are taken up by cells
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
This disclosure provides novel peptide hydrogels containing encapsulated nanoparticles comprising nucleic acid molecules (such as miRNA) that can undergo multiple gel-to-solution (gel-sol) and solution-to-gel (sol-gel) phase transitions, and their use, such as for controlled delivery of nucleic acid molecules to a subject.